China Resources Pharmaceutical Group
Market Cap
HK$28.5b
Last Updated
2020/06/03 13:33 UTC
Data Sources
Company Financials +
Executive Summary
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in the People’s Republic of China.
Rewards
Risk Analysis
Snowflake Analysis
Good value with adequate balance sheet.
Similar Companies
Share Price & News
How has China Resources Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3320's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
4.4%
3320
7.4%
HK Pharmaceuticals
5.8%
HK Market
1 Year Return
-54.5%
3320
11.8%
HK Pharmaceuticals
-4.0%
HK Market
Return vs Industry: 3320 underperformed the Hong Kong Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: 3320 underperformed the Hong Kong Market which returned -6.5% over the past year.
Shareholder returns
| 3320 | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.4% | 7.4% | 5.8% |
| 30 Day | -3.0% | 11.2% | 4.0% |
| 90 Day | -30.2% | 0.3% | -2.6% |
| 1 Year | -54.5%-54.5% | 13.3%11.8% | -0.6%-4.0% |
| 3 Year | -49.5%-50.7% | 18.6%13.4% | 1.3%-9.2% |
| 5 Year | n/a | 30.7%21.1% | -9.2%-23.5% |
Price Volatility Vs. Market
How volatile is China Resources Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Should China Resources Pharmaceutical Group Limited (HKG:3320) Be Part Of Your Dividend Portfolio?3 weeks ago | Simply Wall St
What Type Of Shareholder Owns China Resources Pharmaceutical Group Limited's (HKG:3320)?1 month ago | Simply Wall St
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?Valuation
Is China Resources Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
8.66x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 3320 (HK$4.53) is trading above our estimate of fair value (HK$2.24)
Significantly Below Fair Value: 3320 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 3320 is good value based on its PE Ratio (8.7x) compared to the Pharmaceuticals industry average (10.3x).
PE vs Market: 3320 is good value based on its PE Ratio (8.7x) compared to the Hong Kong market (9.4x).
Price to Earnings Growth Ratio
PEG Ratio: 3320 is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: 3320 is good value based on its PB Ratio (0.7x) compared to the HK Pharmaceuticals industry average (1.1x).
Next Steps
Future Growth
How is China Resources Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
9.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3320's forecast earnings growth (9.2% per year) is above the savings rate (1.6%).
Earnings vs Market: 3320's earnings (9.2% per year) are forecast to grow slower than the Hong Kong market (16.9% per year).
High Growth Earnings: 3320's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3320's revenue (7.2% per year) is forecast to grow slower than the Hong Kong market (10.6% per year).
High Growth Revenue: 3320's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3320's Return on Equity is forecast to be low in 3 years time (8.6%).
Next Steps
Past Performance
How has China Resources Pharmaceutical Group performed over the past 5 years?
12.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3320 has high quality earnings.
Growing Profit Margin: 3320's current net profit margins (1.6%) are lower than last year (2.1%).
Past Earnings Growth Analysis
Earnings Trend: 3320's earnings have grown by 12.7% per year over the past 5 years.
Accelerating Growth: 3320's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 3320 had negative earnings growth (-17.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: 3320's Return on Equity (7.3%) is considered low.
Next Steps
Financial Health
How is China Resources Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 3320's short term assets (HK$132.9B) exceed its short term liabilities (HK$106.7B).
Long Term Liabilities: 3320's short term assets (HK$132.9B) exceed its long term liabilities (HK$13.8B).
Debt to Equity History and Analysis
Debt Level: 3320's debt to equity ratio (57.7%) is considered high.
Reducing Debt: 3320's debt to equity ratio has reduced from 101.1% to 57.7% over the past 5 years.
Debt Coverage: 3320's debt is well covered by operating cash flow (20.3%).
Interest Coverage: 3320's interest payments on its debt are not well covered by EBIT (2.7x coverage).
Balance Sheet
Next Steps
Dividend
What is China Resources Pharmaceutical Group's current dividend yield, its reliability and sustainability?
2.43%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 3320's dividend (2.43%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.5%).
High Dividend: 3320's dividend (2.43%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.2%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 3320 has been paying a dividend for less than 10 years.
Growing Dividend: 3320's dividend payments have increased, but the company has only paid a dividend for 3 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (21%), 3320's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 3320's dividends in 3 years are forecast to be well covered by earnings (20.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.9yrs
Average management tenure
CEO
Yuewei Han (51yo)
0.67
Tenure
HK$518,000
Compensation
Mr. Yuewei Han serves as Chief Executive Officer and Executive Director at China Resources Pharmaceutical Group Limited since October 22, 2019. He has been Chief Executive Officer of China Resources Health ...
CEO Compensation Analysis
Compensation vs Market: Yuewei's total compensation ($USD66.83K) is below average for companies of similar size in the Hong Kong market ($USD492.58K).
Compensation vs Earnings: Insufficient data to compare Yuewei's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 0.67yr | HK$518.00k | 0.0048% HK$1.4m | |
| Executive Vice Chairman of the Board | 0.50yr | HK$2.92m | no data | |
| CFO, VP & Executive Director | 0.92yr | HK$780.00k | no data | |
| Chief Information Officer & VP | 4.5yrs | no data | no data | |
| Chief Legal Advisor | 6.25yrs | no data | no data | |
| Senior Vice President | 6.5yrs | no data | no data | |
| Senior Vice President | 6.5yrs | no data | no data | |
| Senior Vice President | 3yrs | no data | no data | |
| Assistant President | 4yrs | no data | no data | |
| Assistant President | 3.75yrs | no data | no data |
3.9yrs
Average Tenure
48yo
Average Age
Experienced Management: 3320's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 0.67yr | HK$518.00k | 0.0048% HK$1.4m | |
| Executive Vice Chairman of the Board | 0.50yr | HK$2.92m | no data | |
| CFO, VP & Executive Director | 0.92yr | HK$780.00k | no data | |
| Independent Non-Executive Director | 4yrs | HK$300.00k | no data | |
| Non-Executive Director | 4yrs | no data | no data | |
| Independent Non-Executive Director | 4yrs | HK$300.00k | no data | |
| Non-Executive Chairman | 1.25yrs | HK$4.32m | no data | |
| Independent Non-Executive Director | 4yrs | HK$300.00k | no data | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 1.5yrs | no data | no data | |
| Independent Non-Executive Director | 2.83yrs | HK$300.00k | no data |
2.2yrs
Average Tenure
55yo
Average Age
Experienced Board: 3320's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 3320 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
China Resources Pharmaceutical Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: China Resources Pharmaceutical Group Limited
- Ticker: 3320
- Exchange: SEHK
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$28.460b
- Shares outstanding: 6.28b
- Website: https://www.crpharm.com
Number of Employees
Location
- China Resources Pharmaceutical Group Limited
- China Resources Building
- 41st Floor
- Wan Chai
- Hong Kong
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 3320 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Oct 2016 |
| 640 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Oct 2016 |
| 3320 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Oct 2016 |
| 3320 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Oct 2016 |
Biography
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, hematology, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, and therapeutic infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2019, the company operated 852 retail pharmacies under the CR Care and Teck Soon Hong. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. China Resources Pharmaceutical Group Limited was founded in 2007 and is headquartered in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/03 13:33 |
| End of Day Share Price | 2020/06/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.